Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.04.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Xixi Ye-Tran und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Grand Hôpital de l'Est Francilien (GHEF), Meaux, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Fibrolamellar carcinomas (FLC) are rare and predominantly advanced hepatic malignancies, lacking a clear consensus on anti-tumor treatments (ATT). The primary objective of the study was to determine whether any ATT appeared to give favorable outcomes in terms of morphological objective response (ORR) and disease control (DCR) rate according to RECIST 1.1 criteria. PATIENTS AND METHODS: This retrospective multicentric French cohort from 14 centers included 44 patients with histologically proven FLC who received at least one ATT (chemotherapy and/or tyrosine kinase inhibitors, TKI) and underwent at least one morphological evaluation. . RESULTS: A total of 40 anti-tumor responses were analyzed after a first line treatment. No complete response was observed, with an ORR in 13 % of cases, a DCR in 55 % of cases and 45 % of disease progression. GEMOX regimen (n = 9) showed an ORR of 11 % and a DCR of 33 %; the combination of doxorubicin and platinum-based chemotherapy (n = 6) achieved an ORR of 33 % and a DCR of 83 %. For TKI, sorafenib (n = 10) and sunitinib (n = 3), there was no objective response, with a DCR of 40 % and 33 % respectively. The median and the 5-years overall survival were 3.3 years and 35 % (95 %CI=[0.23-0.54]) respectively. CONCLUSION: FLC have a poor prognosis; ATT show mild response rate. Further approaches and personalized medicine seem to be an unmet need for patients with FLC and new treatments should be urgently developed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Grand Hôpital de l'Est Francilien (GHEF), Meaux, France.
- Liver Cancer Unit, Assistance Publique - Hôpitaux de Paris, Beaujon University Hospital, Clichy, France.
- Gustave Roussy, Department of Children and Adolescents Oncology, Villejuif, F-94805, France.
- Medical Oncology - Lille University Hospital - Lille, France.
- Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
- Hepato-Gastroenterology Department, University Hospital, Angers, France.
Zitieren
APA
Ye-Tran, X., Bouattour, M., Fresneau, B., Turpin, A., Perret, A., Vitellius, C., Coriat, R., Blanc, J. F., Lequoy, M., Regnault, H., Pietrasz, D., Sefrioui, D., Lecomte, T., Moati, E., Caliez, O., Nguyen-Khac, E., Walter, T., & Hautefeuille, V. (2025). Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.04.016
Vancouver
Ye-Tran X, Bouattour M, Fresneau B, Turpin A, Perret A, Vitellius C, et al. Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.04.016
BibTeX
@article{YeTran2025,
author = {Ye-Tran, Xixi and Bouattour, Mohamed and Fresneau, Brice and Turpin, Anthony and Perret, Audrey and Vitellius, Carole and Coriat, Romain and Blanc, Jean Frederic and Lequoy, Marie and Regnault, Hélène and Pietrasz, Daniel and Sefrioui, David and Lecomte, Thierry and Moati, Emilie and Caliez, Olivier and Nguyen-Khac, Eric and Walter, Thomas and Hautefeuille, Vincent},
title = {Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.04.016}
}
EUVIMED